GH and IGF-1 Elevation: The Primary Axis Endpoint
CJC-1295 ipamorelin benefits documented in published Phase I/II-context human data center on the GH/IGF-1 axis. CJC-1295 at 60–90 µg/kg subcutaneous elevated mean GH by 46% and mean IGF-1 by 45% at one week post-dose in healthy men, with basal GH elevated 7.5-fold and pulsatile secretion preserved.[1] Proteomic analysis confirmed downstream IGF-1-axis activation: immunoglobulin-albumin fragment levels correlated linearly with IGF-1 elevation, and multiple serum protein isoforms shifted in response to GH/IGF-1 axis upregulation.[6]
For GH secretagogues more broadly, MK-677 (25 mg/day, 12 months, n=65) increased fat-free mass +1.1 kg and total body weight +2.7 kg versus placebo, and restored pulsatile GH to young-adult levels in older subjects.[17] These outcomes establish the class-level evidence for GH secretagogue effects; direct CJC-1295/ipamorelin combination data on these endpoints in human subjects have not been published.
Body Composition Outcomes in Preclinical and Clinical Studies
In GHRH-knockout mice, once-daily CJC-1295 at 2 µg/day normalized body weight, length, lean mass, and subcutaneous fat mass versus untreated knockout animals.[5] This GH-deficiency-rescue model demonstrates body composition restoration as a downstream CJC-1295 outcome in a rodent model but does not translate directly to GH-sufficient subjects. Ipamorelin at 100 µg/kg three times daily subcutaneous increased maximum tetanic muscle tension significantly in rats when counteracting glucocorticoid-induced muscle loss.[8]
In GH-intact mice, twice-daily ipamorelin increased relative body fat and elevated serum leptin and food intake via GH-independent mechanisms — an adipogenic effect mechanistically distinct from GH's predicted lipolytic actions.[19] The net body composition effect in any given subject would depend on GH status at baseline, dose, and concurrent dietary conditions.
Bone Mineral Content and Longitudinal Growth in Rodent Studies
Ipamorelin dose-dependently increased longitudinal bone growth rate in adult female rats from 42 µm/day (vehicle) to 52 µm/day over 15 days (p<0.0001); body weight gain also increased while total IGF-1 and IGFBP levels remained unchanged.[4] This finding identified a GH-dependent but IGF-1-independent bone growth pathway for ipamorelin.
Ipamorelin and GHRP-6 at 0.5 mg/kg/day for 12 weeks increased bone mineral content in adult female rats as measured by DXA; the increase reflected expanded bone dimensions (appositional growth) rather than volumetric bone mineral density change, and was distinct from the response to exogenous GH at 3.5 mg/kg.[9] Ipamorelin at 100 µg/kg three times daily produced a 4-fold increase in periosteal bone formation rate in adult rats experiencing glucocorticoid-induced bone loss.[8]
EST. 05 — SIX-SPECIES EVIDENCE BASE
Sleep Architecture and Nocturnal GH Secretion
Ghrelin — the endogenous ligand at the same receptor that ipamorelin binds (GHS-R1a) — administered as intravenous boluses (4 × 50 µg hourly) to seven human subjects enhanced slow-wave sleep and delta-wave activity across the night while reducing REM sleep in the first half of the night; GH and prolactin rose substantially.[12] This human data from ghrelin provides mechanistic context for ipamorelin's potential effect on sleep architecture via GHS-R1a agonism, but published controlled sleep data for ipamorelin specifically are not available in the peer-reviewed record.
The physiological link between slow-wave sleep and the nocturnal GH pulse is well-established: the largest endogenous GH release event of the day typically occurs within minutes of the first slow-wave sleep period. GHS-R1a agonism at that circadian window — when somatostatin tone is at its nadir — is a pharmacologically coherent timing target in the secretagogue research literature.
Gastrointestinal Motility in the Ipamorelin Literature
Ipamorelin dose-dependently restored gastrointestinal function in a rat model of postoperative ileus at IV doses of 0.01–1 mg/kg four times daily for 2 days: repeated dosing significantly increased cumulative fecal output, food intake, and body weight gain by leveraging GHS-R1a agonism on enteric ghrelin receptors.[10] This GI-motility endpoint reflects a pharmacological property of GHS-R1a agonists distinct from the GH-axis mechanism — ghrelin receptors are expressed throughout the enteric nervous system and regulate gastric emptying and intestinal motility independently of pituitary GH release.
This finding was cited in ipamorelin's Phase I/II clinical development for postoperative ileus (NCT00672074, Rhythm Pharmaceuticals/Helsinn), establishing the GI-motility endpoint as a distinct clinical rationale from the GH-axis growth and body composition endpoints.
Evidence for Efficacy in Controlled Studies
The published record supports the following evidence-based conclusions:
- CJC-1295 Phase I/II-context trials demonstrated statistically significant increases in mean GH and IGF-1 versus baseline in healthy men.[1]
- Ipamorelin's GH-stimulating effects in healthy subjects were confirmed in Phase I safety data.
- GHS synergy — greater-than-additive GH release from GHRH + GHS combination — has been confirmed across five species.[13]
- Downstream bone, body composition, GI motility, and sleep-architecture outcomes have been measured in rodent models and, for class-level GHS agents, in human trials.
Combination CJC-1295/ipamorelin human efficacy data remain limited to the preclinical and pharmacokinetic record. What Phase II-level evidence shows is sustained IGF-1 elevation under CJC-1295 alone; what class-level GHS data show is fat-free mass gains, physical performance improvements, and GH restoration to young-adult levels in older subjects with oral agents. The combination's human efficacy record in head-to-head controlled trials does not yet exist in peer-reviewed literature.
Timeline of Observed Outcomes in Research Protocols
CJC-1295 Phase II trials showed IGF-1 elevation within 2 weeks of dosing; sustained IGF-1 elevation persisted for up to 28 days post-dose with the DAC form.[1] Body composition endpoints in animal studies showed measurable changes at 4–8 weeks of sustained dosing: bone growth rate increases were measured over 15-day protocols;[4] periosteal bone formation rate changes over multi-week glucocorticoid-counteraction protocols;[8] and BMC increases over 12-week protocols.[9] Human combination outcome timelines have not been published.